A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Starting soon · Phase 3

Conditions studied: Diabetes Mellitus, Type 2

In brief

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.

Key facts

Study ID

NCT07668336

Run by

Eli Lilly and Company

People needed

170

Starts

2026-09-01

Expected to finish

2030-03-01

Last updated by the study team

2026-07-20

Who can join

Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin
• Have HbA1c > 6.5% to ≤ 11.0% at screening
• Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of >85th percentile

You may not qualify if…

• Have type 1 diabetes
• After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
• Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening
• Have a history of pancreatitis or gallbladder disease
• Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
• Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or (SGLT2) inhibitors within 90 days prior to screening
• Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 90 days prior to screening

Where it is running

• Rady Children's Hospital — San Diego, California, United States
• Stamford Therapeutics Consortium — Stamford, Connecticut, United States
• Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP) — Atlanta, Georgia, United States
• CenExel iResearch, LLC — Decatur, Georgia, United States
• Medical Research Partners — Ammon, Idaho, United States
• Cotton O'Neil Diabetes & Endocrinology — Topeka, Kansas, United States
• SUNY Upstate Medical University — Syracuse, New York, United States
• Advantage Clinical Trials — The Bronx, New York, United States
• Central States Research — Tulsa, Oklahoma, United States
• Frontier Clinical Research, LLC — Smithfield, Pennsylvania, United States
• Vanderbilt Health One Hundred Oaks — Nashville, Tennessee, United States
• Gadolin Research — Beaumont, Texas, United States
• Driscoll Children's Hospital — Corpus Christi, Texas, United States
• Proactive Clinical Research LLC — Edinburg, Texas, United States
• Consano Clinical Research, LLC — Shavano Park, Texas, United States
• Victoria Clinical Research Group — Victoria, Texas, United States
• Cliniques universitaires Saint-Luc — Brussels, Belgium
• UZ Gent — Ghent, Belgium
• UZ Leuven — Leuven, Belgium
• Instituto de Pesquisa clinica de Campinas — Campinas, Brazil
• Centro de Pesquisa Sao Lucas — Campinas, Brazil
• Cendi - Endocrinologia e Diabetes — Goiânia, Brazil
• Instituto Méderi de Pesquisa e Saúde — Passo Fundo, Brazil
• Instituto da Crianca com Diabetes — Porto Alegre, Brazil
• Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.